Choosing the right drug: status and future of endocannabinoid research for the prevention of drug-seeking reinstatement.
Journal
Current opinion in pharmacology
ISSN: 1471-4973
Titre abrégé: Curr Opin Pharmacol
Pays: England
ID NLM: 100966133
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
06
06
2020
revised:
06
08
2020
accepted:
25
08
2020
pubmed:
18
10
2020
medline:
26
10
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
Prolonged exposure to drugs of abuse leads to severe alterations in mesocorticolimbic dopamine circuitry deeply implicated in substance use disorders. Despite considerable efforts, few medications to reduce relapse rates are currently available. To solve this issue, researchers are uncovering therapeutic opportunities offered by the endocannabinoid system. The cannabinoid receptor type 1 (CB
Identifiants
pubmed: 33068883
pii: S1471-4892(20)30065-5
doi: 10.1016/j.coph.2020.08.014
pii:
doi:
Substances chimiques
Endocannabinoids
0
Ligands
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
29-38Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.